10q10k10q10k.net
Nuvation Bio Inc.

Nuvation Bio Inc.NUVBEarnings & Financial Report

NYSE · Health Care · Pharmaceutical Preparations

Nuvation Bio Inc. is a clinical-stage biopharmaceutical company focused on researching and developing targeted oncology therapies to address unmet medical needs in difficult-to-treat cancer types. Its core pipeline features novel drug candidates targeting key oncogenic pathways, with primary operations and market presence centered in North America.

Q4 2025Q3 2025Q4 2024Q1 2024Q3 2023Q2 2023

NUVB Q4 FY2025 Key Financial Metrics

Revenue

$41.9M

Gross Profit

N/A

Operating Profit

$-34.0M

Net Profit

N/A

Gross Margin

N/A

Operating Margin

-81.3%

Net Margin

N/A

YoY Growth

633.1%

EPS

$-0.11

Nuvation Bio Inc. Q4 FY2025 Financial Summary

Nuvation Bio Inc. reported revenue of $41.9M (up 633.1% YoY) for Q4 FY2025, with a net profit of N/A (N/A margin).

Key Financial Metrics

Total Revenue$41.9M
Net ProfitN/A
Gross MarginN/A
Operating Margin-81.3%
Report PeriodQ4 FY2025

Nuvation Bio Inc. Quarterly Revenue & Net Profit History

Nuvation Bio Inc. results over the last 6 reported quarters, including revenue, net profit and year-over-year growth.

QuarterRevenueRevenue YoYNet ProfitNet Margin
Q4 FY2025$41.9M+633.1%N/AN/A
Q3 FY2025$13.1M+1704.7%$-55.8M-425.2%
Q4 FY2024$5.7M—N/AN/A
Q1 FY2024$0—$-14.8MN/A
Q3 FY2023$0—$-19.6MN/A
Q2 FY2023$0—$-20.6MN/A

Income Statement

Q2 2023Q3 2023Q1 2024Q4 2024Q3 2025Q4 2025
Revenue$0$0$0$5.7M$13.1M$41.9M
YoY GrowthN/AN/AN/AN/A1704.7%633.1%

Balance Sheet

Q2 2023Q3 2023Q1 2024Q4 2024Q3 2025Q4 2025
Assets$641.4M$630.9M$613.1M$540.6M$601.6M$594.8M
Liabilities$16.8M$19.3M$19.1M$76.8M$275.7M$289.1M
Equity$624.6M$611.6M$594.0M$463.8M$325.9M$305.7M

Cash Flow

Q2 2023Q3 2023Q1 2024Q4 2024Q3 2025Q4 2025
Operating CF$-17.5M$-16.2M$-15.7M$-46.3M$-52.9M$-29.7M